Table 3.

ORs and 95% CIs for the risk of postmenopausal breast cancer according to quartiles of prediagnostic biomarkers

Cases/controlsaBasic modelb OR (95% CI)Adjusted Ic OR (95% CI)Adjusted IId OR (95% CI)
Leptin, ng/mL
 ≤10.4118/1771.001.001.00
 10.5–18.9169/1761.40 (1.02–1.92)1.39 (1.01–1.91)1.33 (0.96–1.84)
 19.0–35.1216/1771.90 (1.39–2.59)1.87 (1.34–2.60)1.74 (1.24–2.44)
 >35.1203/1761.94 (1.37–2.75)1.90 (1.28–2.80)1.78 (1.19–2.65)
Ptrende< 0.0010.0010.014
Adiponectin, μg/mL
 ≤5.7182/1771.001.001.00
 5.8–10.0210/1761.14 (0.85–1.53)1.15 (0.86–1.54)1.18 (0.87–1.58)
 10.1–16.1158/1760.86 (0.63–1.16)0.90 (0.66–1.23)0.92 (0.67–1.27)
 >16.1156/1770.82 (0.59–1.14)0.88 (0.63–1.23)0.94 (0.66–1.32)
Ptrende0.0810.2220.397
Leptin:adiponectin
 ≤0.8110/1771.001.001.00
 0.9–2.2188/1751.74 (1.27–2.38)1.71 (1.24–2.36)1.63 (1.18–2.26)
 2.3–5.2212/1781.97 (1.43–2.71)1.91 (1.37–2.68)1.77 (1.25–2.50)
 >5.2196/1761.91 (1.36–2.68)1.82 (1.25–2.66)1.70 (1.15–2.51)
Ptrende0.0050.0350.153
CRP, mg/L
 ≤0.9146/1771.001.001.00
 1.0–1.9175/1821.21 (0.89–1.66)1.19 (0.87–1.63)1.20 (0.87–1.64)
 2.0–4.0199/1761.46 (1.06–2.03)1.41 (1.01–1.96)1.40 (1.01–1.96)
 >4.0186/1711.41 (1.01–1.96)1.33 (0.95–1.87)1.31 (0.94–1.84)
Ptrende0.0140.0450.246
  • aCases and controls were matched on age of birth (±1 year), location (HI or CA), ethnicity, date of blood draw (±6 months), time of blood draw (±2 hours), hours fasting before blood draw (<6, 6–< 8, 8–< 10, ≥10), and hormone replacement therapy use at blood draw (current vs. not current).

  • bEstimated from conditional logistic regression with matched sets as strata.

  • cAdditionally adjusted for BMI (kg/m2).

  • dAdditionally adjusted for CRP, history of diabetes, and history of hypertension.

  • eP value for the Wald test of Ho: β = 0 for the natural log-transformed continuous variable.